Thus, shareholders might cash a gross dividend of RON0.072/share, compared to RON0.048/share distributed last year from the 2012 profit.
Zentiva, a unit of French drug maker Sanofi-Aventis, paid dividends of RON20 million in 2013, or 62% of its 2012 profit of RON32.2 million.
In 2013, Zentiva invested RON10.76 million in its production facilities and equipment in 2013. The company’s total revenue increased 15% on the year to RON301.8 million, while overall expenditure was at RON248.8 million, up 12% from 2012.
According to the latest available data, French group Sanofi-Aventis owns 81.6% of Zentiva Romania’s shares.
On the Romanian market, the French drugmaker operates through two separate units: Sanofi-Aventis Romania and Zentiva Romania. Sanofi-Aventis is the leader of the domestic pharmaceutical market, with a share of 7.4% and sales of RON873.2 million between October 2012 and September 2013, according to market researcher Cegedim.
On the Bucharest stock exchange Monday, Zentiva closed down 0.95%, at RON1.04 a share. (EUR1=RON4.4793)